FMP
Edesa Biotech, Inc.
EDSA
NASDAQ
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
1.73 USD
-0.02 (-1.16%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Dr. Pardeep Nijhawan FRCPC, M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.edesabiotech.comexchange
NASDAQ
Description
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
CIK
0001540159
ISIN
CA27966L3065
CUSIP
27966L108
Address
100 Spy Court
Phone
289-800-9600
Country
CA
Employee
16
IPO Date
Jun 21, 2010
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
EDSA Financial Summary
CIK
0001540159
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
27966L108
ISIN
CA27966L3065
Country
CA
Price
1.73
Beta
0.84
Volume Avg.
30.84k
Market Cap
6M
Shares
-
52-Week
1.55-5.99
DCF
0.32
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.9
P/B
-
Website
https://www.edesabiotech.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EDSA News
It looks like there's no news available.
